{"id":"hib-mcc","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, redness, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL4298703","moleculeType":"Unknown","molecularWeight":"1727.93"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine works by conjugating the Hib capsular polysaccharide to meningococcal C protein carrier, enhancing immunogenicity and inducing both T-cell and B-cell responses. This conjugation approach improves the immune response compared to unconjugated polysaccharide vaccines, particularly in young children, providing protection against invasive Hib and meningococcal C disease.","oneSentence":"Hib-MCC is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide with meningococcal C conjugate to stimulate immune protection against both pathogens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:12.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive Haemophilus influenzae type b disease"},{"name":"Prevention of invasive meningococcal C disease"}]},"trialDetails":[{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MENITORIX®"],"phase":"phase_3","status":"active","brandName":"Hib-MCC","genericName":"Hib-MCC","companyName":"MCM Vaccines B.V.","companyId":"mcm-vaccines-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"Hib-MCC is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide with meningococcal C conjugate to stimulate immune protection against both pathogens. Used for Prevention of invasive Haemophilus influenzae type b disease, Prevention of invasive meningococcal C disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}